Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trial delays, lack of financing, Mono is still more than 1 year away from completed trials, combo therapy more than 1 year away from approval, no Tutes ownership .... it makes sense that we’re less than 200 Mill mkt cap. Much can change once the Prostagene deal is signed and prognostic test is approved / licensed
Inch ? Meant bunch.
Because we don’t know what kind of bull shirt the FDA will pull next.
Make opioids pills more available for abuse while restricting IV opioids at hospitals ! Doubly stupid; making two problems worse.
Why invest in an innovative company if there’s a inch of unprepared ignorant paper pushers who don’t understand what they are reviewing ? Some of FDA people were AWFUL yesterdays AdCom
What point is there investing in medical developments ?
Yes losing only Losing 15% is good. Everyday has been down 15% or more
That’s why it was rejected you can’t sell as many drugs while using Oli
Government seems to act to perpetuate the opioid crisis
They had tiny amounts of shares according to Fintel
Can’t. They’re in a quiet period.
FUD. No other reason.
The organizers of yesterday’s events.
Fintel. Not many shares total. More shares were bought by other Tutes
38 Tutes DID sell all of their TRVN, but almost all had very few shares. #3 shareholder NEA, used to be led by the current FDA commissioner. Curious.
And the asking for more data would take ... 2 or 3 quarters ?
So the “news” is that opioids can be addictive. Huh, who woulda thought ? They still give out morphine in hospitals; Oli is an IV, not gonna be administered outside hosps.
If earnings come in at 5 cents; that’s a run rate of 20 cents / year. That’s a PE of 13. With revenue growth of 129% y o y ? Should be a few times this on a PE basis. Revenues or connections would give different figures. Connections growing at 200+% ?? Undervalued in any case.
Wall Street is either stupid or asleep or hasn’t heard of Parateum yet.
Yeah, signif appreciation before AdCom on Oct 11. Who knows where day after that. Analysts say 10+ in 12 months
Now it’s less than 400% upside, but still
And if we don’t ... we’re delisted ?
< nervous laugh>
Wow. Suddenly TRVN is my second largest position. And another day like this tomorrow would make it first.
Why are many of the trades for 100 shares ? 4 Mill already total, I don’t get it.
No messages in an entire decade ??
My curse is upon you !!! Once I buy a stock, it is cursed. Sorry.
Bought today. Plenty of expansion opportunities and increasing scale lifts margins. Plus they acquire companies on the cheap. Software as a Service
There is money that can be made. Only After Prostagene and licensing deals.
Yeah, but that company has $28 Mill in revenue. For VSTM, With only 2,000 patients / year that will mean $150+ Mill / year. Plus royalties from China, Europe, Japan ...
Your previous post said it was great news for patients. Mighty inconsistent from one post to the next.
Drug cost = $11,800
Closed at 216 up from 188.3 shekels ? 1 shekel is 28 cents .... so $0.61 up from $0.54. Hmm. Perhaps my math or facts is / are wrong.
GRMD02 improves Keytruda effectiveness by 4 times !
GALT published Keytruda head & neck 16% ORR, Complete response 5%, with GR-MD-02 67% and 33%.
Inhibition of the other HIV co-receptor is thought to thwart metastatic pancreatic cancer also? http://www.cancernetwork.com/aacr-street-team/inhibit-cxcr4-treat-crc-and-pancreatic-cancer
Take $850 Mill for combined company. Multiply by 27.5% for Tpiv’s share = $233.7 Mill. Current mkt cap by Yahoo = $132 Mill. We should be 77% higher according to Nomura. ??
At least 100 with realistic dilution. That’ll do.
Well, it *looks* like an approval. We will see if that really does mean anything.
Yes, I agree. That chart says a gradual increase until about 20 days before announcement; then a slight decline. VSTM has gone up steadily up until about 30 days before announcement, then declined.
Viking ... Galectin ... either one is OK with me.